Mesenchymal stem cells (MSCs) are advantageous over other stem cells types for a variety of reasons. First, they avoid the ethical issues that surround embryonic stem cell research.
Second, Repeated studies have found MSCs to be immune-privileged, which makes them an advantageous cell type for allogeneic transplantation. MSCs reduce both the risks of rejection and complications of transplantation.
Third, there have been advances in the use of umbilical cord mesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, and bone fractures, because MSCs can exert regenerative effects through homing to sites of damage, paracrine signalling, regulating immune responses, and positively affecting the microenvironment.
During culture, MSCs are expanded in numbers to reach a therapeutically beneficial dose. However, every time a stem cell divides (self-renews) it loses some of its abilities. In a way each time a cell divides it ages, becoming slower and less able to perform its specialist tasks. At Trinity Stem Cell Treatment Center, we utilize only 2 grades of UCMSCs – Premium: Passage 1 Mesenchymal Stem Cells (P1 MSCs) (with higher rates of efficiency) and 3 Mesenchymal Stem Cells (P3 MSCs).
MSCs lack the co-stimulatory molecules of the B7 family that are required to initiate an immune response. This allows the administration of MSC preparations across immune system MHC barriers (Major Histocompatibility Complex) without concern for immunological rejection or the need for immunosuppression. This makes Wharton’s Jelly umbilical derived Mesenchymal stem cells a universal stem cell source, which does not require blood or tissue typing to be received safely.